超小剂量地西他滨治疗中危-1型骨髓增生异常综合征10例的临床观察

Study of ultro-low dose Decitabine in patients with intermediate-1 risk myelodysplastic syndromes

目的探讨超小剂量地西他滨治疗中危-1型骨髓增生异常综合征的疗效及副反应。方法收集2016年1月至2017年1月中国医科大学附属盛京医院血液科10例中危-1型骨髓增生异常综合征患者的临床资料。所有患者接受皮下注射地西他滨10 mg/d,第1~3天,第8、15、22天。32 d为1个疗程。评估其疗效及副反应。结果 6例例存在MDS相关基因突变。1个疗程结束时4例获得了临床改善,其中1例部分缓解(PR),3例血液学改善(HI),6例疾病稳定(SD)。3例患者完成3个疗程治疗,疗效评估显示,2例获得了临床改善,1例(33.3%)完全缓解(CR),1例血液学改善,1例SD。出现骨髓抑制4例,白细胞减少1例,贫血1例,血小板减少3例;2例出现严重的血小板减少。结论超小剂量地西他滨治疗中危-1型骨髓增生异常综合征安全有效。

Objective To assess the efficacy and tolerability of ultro-low dose of decitabine in patients with intermediate-1 risk myelodysplastic syndrome （MDS）. Method Ten Patients received decitabine, 10mg/d ,d1~3, dS, d15, d22, every 32 days. Evaluate the effect and adverse event. Results 6/10（60%） patients had gene mutation associated with MDS. After one circle treatment,the OIR was 40%, PR rate was 10%, HI was 30%, SD was 60%. After three circles treatment ,the OIR was 67%, CR rate was 33.3%, HI was 33.3%, SD was 33.3%. 40% patients showed bone marrow depression, neutropenia 10%,anemia 10%, thrombocytopenia 10%, ≥3grade thrombocytopenia 20%. Conclusion Ultra low dose ofdecitabine was efficient and safe to treat intermediate-1 risk MDS patients.